Latest Period
Q2 2026
Security Snapshot
ARROWHEAD PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (ARWR) Institutional Ownership
CUSIP: 04280A100
13F Institutional Holders and Ownership History from Q4 2014 to Q2 2026
Institutions Reporting
495
Shares (Excl. Options)
119,134,121
Price
$81.51
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ARWR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 119,134,121
- Total 13F value
- $9,715,821,798
- Portfolio coverage rank
- 0.01%
- Share change
- -1,267,739
- Value change
- -$61,454,353
- Number of holders
- 495
- Shares outstanding
- 143,396,089
- SEC-reported price per share
- $87.32
- Insider filing price
- $87.32
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 04280A100.
- 495 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 435 to 495 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,574,478,351 to $9,715,821,798.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 495 institutions filings for Q2 2026.
Security key
04280A100
Latest holder period
Q2 2026
13F holders
495
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
ARWR full holder history
ARROWHEAD PHARMACEUTICALS, INC. SEC filings
ARROWHEAD PHARMACEUTICALS, INC. company facts
ARROWHEAD PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 04280A100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ARWR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | -18% | $1,160,094,743 | -$234,059,144 | 14,232,545 | -17% | BlackRock, Inc. | 30 Jun 2026 |
| Avoro Capital Advisors LLC | 9.6% | +17% | $1,202,219,620 | +$200,547,776 | 13,823,383 | +20% | Avoro Capital Advisors LLC | 30 Jun 2026 |
| FMR LLC | 5.2% | $478,720,814 | 7,349,107 | FMR LLC | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $443,997,071 | 7,081,293 | Vanguard Capital Management | 31 Mar 2026 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5% | -13% | $555,295,014 | -$76,973,146 | 6,384,903 | -12% | Vanguard Portfolio Management | 30 Jun 2026 |
| STATE STREET CORP | 4.6% | -10% | $106,970,030 | -$10,547,360 | 6,371,056 | -9% | STATE STREET CORPORATION | 30 Jun 2025 |
As of 30 Jun 2026, 495 institutional investors reported holding 119,134,121 shares of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (ARWR). This represents 83% of the company’s total 143,396,089 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
60%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | 14,830,553 | -18% | 0.02% | $1,208,838,379 |
| Avoro Capital Advisors LLC | 7.9% | 11,355,555 | +6.1% | 8.3% | $925,591,288 |
| FMR LLC | 5.6% | 8,039,804 | +11% | 0.03% | $655,324,429 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4% | 6,351,355 | -11% | 0.02% | $517,698,946 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 6,110,953 | +1.3% | 0.01% | $498,103,779 |
| STATE STREET CORP | 4% | 5,694,640 | -12% | 0.01% | $464,170,106 |
| NORGES BANK | 2.7% | 3,896,536 | 0.03% | $317,606,649 | |
| Invesco Ltd. | 2.7% | 3,883,976 | +18% | 0.03% | $316,582,884 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 3,530,612 | -17% | 0.02% | $298,813,042 |
| FRED ALGER MANAGEMENT, LLC | 2.3% | 3,301,919 | -1.2% | 0.9% | $269,139,418 |
| BAKER BROS. ADVISORS LP | 1.4% | 1,992,783 | 0% | 0.81% | $162,431,742 |
| Siren, L.L.C. | 1.2% | 1,715,476 | +6.2% | 2.8% | $139,828,449 |
| Vestal Point Capital, LP | 1.1% | 1,575,000 | -31% | 3% | $128,378,250 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 0.97% | 1,389,055 | -12% | 1.2% | $113,221,873 |
| FIRST TRUST ADVISORS LP | 0.94% | 1,352,918 | +807% | 0.06% | $110,276,346 |
| Driehaus Capital Management LLC | 0.94% | 1,350,556 | +13% | 0.64% | $110,083,820 |
| Jupiter Topco LLC | 0.85% | 1,221,596 | 0% | 0.04% | $99,622,870 |
| NORTHERN TRUST CORP | 0.83% | 1,192,868 | -28% | 0.01% | $97,230,671 |
| DIMENSIONAL FUND ADVISORS LP | 0.82% | 1,181,608 | +94% | 0.02% | $96,310,585 |
| GOLDMAN SACHS GROUP INC | 0.8% | 1,150,007 | -34% | 0.01% | $93,737,071 |
| BANK OF AMERICA CORP /DE/ | 0.79% | 1,139,810 | +7.1% | 0.01% | $92,905,915 |
| Hood River Capital Management LLC | 0.78% | 1,120,747 | +6.1% | 0.66% | $91,352,088 |
| Holocene Advisors, LP | 0.77% | 1,106,177 | 0.21% | $90,164,487 | |
| MORGAN STANLEY | 0.76% | 1,084,835 | +13% | 0% | $88,425,108 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.67% | 964,479 | -28% | 0.01% | $78,614,683 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
47
Latest
Q2 2026
Rows shown
1-25 of 47
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 119,134,121 | $9,715,821,798 | -$61,454,353 | $81.51 | 495 |
| 2026 Q1 | 120,798,623 | $7,574,478,351 | +$292,926,429 | $62.70 | 435 |
| 2025 Q4 | 115,966,805 | $7,699,721,958 | +$347,241,347 | $66.39 | 400 |
| 2025 Q3 | 110,897,224 | $3,823,917,269 | +$261,693,126 | $34.49 | 300 |
| 2025 Q2 | 105,716,035 | $1,671,181,802 | +$44,748,514 | $15.80 | 279 |
| 2025 Q1 | 103,362,113 | $1,318,228,654 | +$23,656,546 | $12.74 | 258 |
| 2024 Q4 | 99,701,045 | $1,874,384,692 | +$32,738,534 | $18.80 | 267 |
| 2024 Q3 | 97,715,477 | $1,892,897,060 | -$93,908,485 | $19.37 | 267 |
| 2024 Q2 | 97,822,928 | $2,542,052,894 | +$57,202,679 | $25.99 | 272 |
| 2024 Q1 | 96,658,787 | $2,763,026,175 | +$544,741,705 | $28.60 | 267 |
| 2023 Q4 | 77,504,804 | $2,371,960,338 | +$86,943,186 | $30.60 | 265 |
| 2023 Q3 | 74,643,254 | $2,005,663,054 | +$41,168,266 | $26.87 | 253 |
| 2023 Q2 | 71,799,685 | $2,559,646,627 | -$10,508,327 | $35.66 | 267 |
| 2023 Q1 | 72,976,301 | $1,851,849,623 | -$23,671,296 | $25.40 | 250 |
| 2022 Q4 | 73,474,031 | $2,977,955,799 | +$97,292,640 | $40.56 | 276 |
| 2022 Q3 | 71,284,086 | $2,353,949,365 | -$40,859,478 | $33.05 | 264 |
| 2022 Q2 | 72,095,607 | $2,538,257,759 | +$100,531,936 | $35.21 | 263 |
| 2022 Q1 | 69,254,530 | $3,184,523,615 | +$35,685,819 | $45.99 | 294 |
| 2021 Q4 | 67,961,552 | $4,505,834,422 | +$55,872,415 | $66.30 | 297 |
| 2021 Q3 | 66,549,683 | $4,154,048,742 | -$66,618,101 | $62.43 | 282 |
| 2021 Q2 | 66,896,948 | $5,539,659,575 | -$140,144,186 | $82.82 | 304 |
| 2021 Q1 | 68,464,454 | $4,541,675,803 | -$29,602,424 | $66.31 | 281 |
| 2020 Q4 | 69,478,160 | $5,331,874,119 | +$80,806,659 | $76.73 | 302 |
| 2020 Q3 | 68,146,322 | $2,935,188,814 | -$17,523,513 | $43.06 | 252 |
| 2020 Q2 | 68,613,840 | $2,962,938,209 | +$129,556,464 | $43.19 | 238 |